Chris Nave

Investing Profile

Sweet spot: $1.5M Range: $100K–$5M Fund: $404.5M

Brandon Capital Partners thesis

Advancell Clinical-stage radiopharmaceutical company developing targeted alpha therapies to treat a broad range of cancers. Aravax Pty Ltd Developing peptide-based immunotherapies for food allergy treatment AstronauTx Cutting-edge biotech company founded to target neurodegenerative diseases by improving disrupted physiological processes leading to dementia. Axelia Oncology Biopharmaceutical company aiming to transform the treatment of checkpoint insensitive cancers through the activation of TLR2/6 engagement of the innate immune response. Azura Ophthalmics Developing first-in-class ophthalmic

Sector and stage focus

  • Seed: Medical Devices, Pharmaceuticals, Education, BioTech, Therapeutics, Health & Hospital Services
  • Pre-seed: Medical Devices, Pharmaceuticals, Education, BioTech, Health & Hospital Services, Therapeutics

Recent investments by Chris Nave

Chris Nave has 1 named past investments in the public record. The most recent:

Company Stage Date Round size
Azura Ophthalmics Series B Oct 2017 $16M

Frequent co-investors

Chris Nave has co-invested with: Heather Preston.

Is Chris Nave a fit for your round?

Upload your pitch deck and see whether Chris Nave appears in your top 20 matches.

Find investors for your deck